WO2006002382A3 - Arrays with cleavable linkers - Google Patents

Arrays with cleavable linkers Download PDF

Info

Publication number
WO2006002382A3
WO2006002382A3 PCT/US2005/022517 US2005022517W WO2006002382A3 WO 2006002382 A3 WO2006002382 A3 WO 2006002382A3 US 2005022517 W US2005022517 W US 2005022517W WO 2006002382 A3 WO2006002382 A3 WO 2006002382A3
Authority
WO
WIPO (PCT)
Prior art keywords
arrays
molecules
cleavable linkers
methods
glycans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/022517
Other languages
French (fr)
Other versions
WO2006002382A2 (en
Inventor
Chi-Huey Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Priority to AU2005258281A priority Critical patent/AU2005258281A1/en
Priority to JP2007518318A priority patent/JP2008504531A/en
Priority to EP05789058A priority patent/EP1771733A2/en
Priority to CA002571431A priority patent/CA2571431A1/en
Publication of WO2006002382A2 publication Critical patent/WO2006002382A2/en
Publication of WO2006002382A3 publication Critical patent/WO2006002382A3/en
Priority to US11/645,273 priority patent/US20070213278A1/en
Priority to US11/645,188 priority patent/US20070213297A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
    • G01N2400/14—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar alpha-D-Glucans, i.e. having alpha 1,n (n=3,4,6) linkages between saccharide units, e.g. pullulan

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)

Abstract

The invention provides arrays of molecules where the molecules (e.g., glycans) are attached to the arrays by cleavable linkers. The invention also provides methods for using these arrays, methods for identifying the structural elements of molecules bound to these arrays by using the cleavable linkers, especially the structural elements that are important for binding to test samples. The invention further provides methods for evaluating whether test samples and test molecules can bind to distinct glycans on the arrays and useful glycans identified using the methods and arrays provided herein.
PCT/US2005/022517 2004-06-24 2005-06-24 Arrays with cleavable linkers Ceased WO2006002382A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2005258281A AU2005258281A1 (en) 2004-06-24 2005-06-24 Arrays with cleavable linkers
JP2007518318A JP2008504531A (en) 2004-06-24 2005-06-24 Array with cleavable linker
EP05789058A EP1771733A2 (en) 2004-06-24 2005-06-24 Arrays with cleavable linkers
CA002571431A CA2571431A1 (en) 2004-06-24 2005-06-24 Arrays with cleavable linkers
US11/645,273 US20070213278A1 (en) 2004-06-24 2006-12-22 Arrays with cleavable linkers
US11/645,188 US20070213297A1 (en) 2004-06-24 2006-12-22 Arrays with cleavable linkers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58271304P 2004-06-24 2004-06-24
US60/582,713 2004-06-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/645,273 Continuation-In-Part US20070213278A1 (en) 2004-06-24 2006-12-22 Arrays with cleavable linkers
US11/645,188 Continuation-In-Part US20070213297A1 (en) 2004-06-24 2006-12-22 Arrays with cleavable linkers

Publications (2)

Publication Number Publication Date
WO2006002382A2 WO2006002382A2 (en) 2006-01-05
WO2006002382A3 true WO2006002382A3 (en) 2006-10-12

Family

ID=35782369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/022517 Ceased WO2006002382A2 (en) 2004-06-24 2005-06-24 Arrays with cleavable linkers

Country Status (6)

Country Link
US (2) US20070213278A1 (en)
EP (1) EP1771733A2 (en)
JP (2) JP2008504531A (en)
AU (1) AU2005258281A1 (en)
CA (1) CA2571431A1 (en)
WO (1) WO2006002382A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11028181B2 (en) 2015-11-12 2021-06-08 Seagen Inc. Glycan-interacting compounds and methods of use
US11253609B2 (en) 2017-03-03 2022-02-22 Seagen Inc. Glycan-interacting compounds and methods of use
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
USRE49435E1 (en) 2014-11-12 2023-02-28 Seagen Inc. Glycan-interacting compounds and methods of use

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CN103131330B (en) * 2008-02-01 2015-09-23 福吉米株式会社 Composition for polishing and use its Ginding process
JP5986745B2 (en) * 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Glycan arrays on PTFE-like aluminum-coated glass slides and related methods
JP5557229B2 (en) * 2009-05-08 2014-07-23 学校法人神奈川大学 Photodegradable heterobivalent crosslinking agent
JP5536765B2 (en) * 2009-05-20 2014-07-02 国立大学法人鳥取大学 Method for detecting pathogenic Neisseria infection using partial sugar chain epitope and vaccine against these bacteria
WO2011000958A1 (en) 2009-07-03 2011-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
US20120190581A1 (en) * 2009-08-25 2012-07-26 The Johns Hopkins University Detection of Auto-Antibodies to Specific Glycans as Diagnostic Tests for Autoimmune Diseases
EP2501711B1 (en) * 2009-11-16 2014-01-08 Centre National De La Recherche Scientifique CNRS Compounds and methods for purifying peptides produced by solid phase peptide synthesis
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
AU2011237629B2 (en) * 2010-04-07 2015-09-17 Glycomimetics, Inc. Glycomimetic compounds and methods to inhibit infection by HIV
WO2011130332A1 (en) * 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
JP6017422B2 (en) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） Erythrocyte binding therapy
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
SI2794626T1 (en) 2011-12-22 2018-02-28 Glycomimetics, Inc. E-selectin antagonist compounds
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
LT2928476T (en) 2012-12-07 2018-05-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
JP6486368B2 (en) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Activation of human iNKT cells using glycolipids containing modified glycosyl groups
TW201620939A (en) 2014-01-16 2016-06-16 中央研究院 Composition and method for treating and detecting cancer
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2017046652A1 (en) * 2015-09-19 2017-03-23 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
KR20240154672A (en) 2014-02-21 2024-10-25 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3129767B1 (en) 2014-03-27 2021-09-01 Academia Sinica Reactive labelling compounds and uses thereof
DK3149045T3 (en) 2014-05-27 2023-03-06 Academia Sinica COMPOSITIONS AND METHODS OF UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODIST EFFECT
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
KR20170003720A (en) 2014-05-27 2017-01-09 아카데미아 시니카 Anti-cd20 glycoantibodies and uses thereof
JP7063538B2 (en) 2014-05-28 2022-05-09 アカデミア シニカ Anti-TNFα sugar-manipulated antibody group and its use
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US20170305950A1 (en) * 2014-10-10 2017-10-26 Siamab Therapeutics, Inc. Glycan analysis and profiling
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
HUE045542T2 (en) 2014-12-03 2019-12-30 Glycomimetics Inc Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
AU2017231749A1 (en) 2016-03-08 2018-09-20 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
CA3037850A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
KR20250052472A (en) * 2017-11-06 2025-04-18 이매틱스 바이오테크놀로지스 게엠베하 Novel engineered t cell receptors and immune therapy using the same
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
EP3732186A1 (en) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
US11707474B2 (en) 2018-03-05 2023-07-25 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
SG11202011078VA (en) 2018-05-09 2020-12-30 Univ Chicago Compositions and methods concerning immune tolerance
CA3103229A1 (en) 2018-06-11 2019-12-19 Merck Sharp & Dohme Corp. Complex molecule substructure identification systems, apparatuses and methods
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2022118862A1 (en) * 2020-12-01 2022-06-09 国立大学法人九州大学 Biomolecule structure detection probe, biomolecule structure detection kit, and method for detecting biomolecule structure

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856496A (en) * 1996-05-23 1999-01-05 Pharmacia & Upjohn S.P.A. Combinatorial solid phase synthesis of a library of indole derivatives
WO2000052018A2 (en) * 1999-03-05 2000-09-08 Massachusetts Institute Of Technology Linkers for synthesis of oligosaccharides on solid supports
DE10041766A1 (en) * 2000-08-25 2002-03-14 Friz Biochem Gmbh Process for marking chemical substances
US20030186226A1 (en) * 1999-03-08 2003-10-02 Brennan Thomas M. Methods and compositions for economically synthesizing and assembling long DNA sequences
WO2004040307A2 (en) * 2002-10-18 2004-05-13 Gkss Forschungszentrum Device and method for analyzing the structure of complex glycostructures and for detecting same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5958703A (en) * 1996-12-03 1999-09-28 Glaxo Group Limited Use of modified tethers in screening compound libraries
JP4202574B2 (en) * 2000-01-11 2008-12-24 Ａｓｐｉｏｎ株式会社 Peptides with affinity for gp120
US20020098513A1 (en) * 2000-02-17 2002-07-25 Glycominds Ltd. Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
WO2002059154A2 (en) * 2001-01-26 2002-08-01 Abgenix, Inc. Neutralizing human monoclonal antibodies against hiv-1, their production and uses
WO2003093511A1 (en) * 2002-04-30 2003-11-13 Merck & Co., Inc. Human papillomavirus multiplexed assay
ATE376672T1 (en) * 2002-08-02 2007-11-15 Glycominds Ltd METHOD FOR DIAGNOSING MULTIPLE SCLERosis
GB0225197D0 (en) * 2002-10-30 2002-12-11 Univ Sheffield Surface
US7592150B2 (en) * 2003-12-03 2009-09-22 Glycominds, Ltd Method for diagnosing diseases based on levels of anti-glycan antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856496A (en) * 1996-05-23 1999-01-05 Pharmacia & Upjohn S.P.A. Combinatorial solid phase synthesis of a library of indole derivatives
WO2000052018A2 (en) * 1999-03-05 2000-09-08 Massachusetts Institute Of Technology Linkers for synthesis of oligosaccharides on solid supports
US20030186226A1 (en) * 1999-03-08 2003-10-02 Brennan Thomas M. Methods and compositions for economically synthesizing and assembling long DNA sequences
DE10041766A1 (en) * 2000-08-25 2002-03-14 Friz Biochem Gmbh Process for marking chemical substances
WO2004040307A2 (en) * 2002-10-18 2004-05-13 Gkss Forschungszentrum Device and method for analyzing the structure of complex glycostructures and for detecting same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRYAN, MARIAN C. ET AL: "Covalent display of oligosaccharide arrays in microtiter plates", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , 126(28), 8640-8641 CODEN: JACSAT; ISSN: 0002-7863, 2004, XP002383116 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49435E1 (en) 2014-11-12 2023-02-28 Seagen Inc. Glycan-interacting compounds and methods of use
US11028181B2 (en) 2015-11-12 2021-06-08 Seagen Inc. Glycan-interacting compounds and methods of use
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
US11253609B2 (en) 2017-03-03 2022-02-22 Seagen Inc. Glycan-interacting compounds and methods of use

Also Published As

Publication number Publication date
US20070213297A1 (en) 2007-09-13
JP2007312776A (en) 2007-12-06
AU2005258281A1 (en) 2006-01-05
EP1771733A2 (en) 2007-04-11
US20070213278A1 (en) 2007-09-13
JP2008504531A (en) 2008-02-14
CA2571431A1 (en) 2006-01-05
WO2006002382A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
EA200702278A1 (en) ANTIBODIES SPECIFIC FOR TGF-BETA 1
WO2005113817A3 (en) Aptamer-nanoparticle conjugates and method of use for target analyte detection
WO2004106380A3 (en) Human-anti-human cd3 binding molecules
WO2006040129A3 (en) Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography
IL191142A0 (en) An isolated nucleic acid which encodes a ligand binding fluorescent indicator, multimeric biosensors and methods of using the same
WO2007041635A3 (en) Fc variants with optimized fc receptor binding properties
WO2006073941A3 (en) Polypeptides that bind br3 and uses thereof
DK1742966T3 (en) Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2007079218A3 (en) Metalloproteinase binding proteins
WO2005017205A3 (en) Nucleic acid mapping using linear analysis
WO2008095905A3 (en) Pathogen binding
WO2005026730A3 (en) Multiplex binding and activity assays
WO2007120766A3 (en) Erythropoietin receptor agonists
WO2005085869A3 (en) Determination of analyte characteristics based upon binding properties
WO2006090073A3 (en) Method and device for separating molecular targets in a complex mixture
WO2009007913A3 (en) Protein labelling with tags comprising isotope-coded sub-tags and isobaric sub-tags
WO2006034278A3 (en) Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
WO2006088700A3 (en) Human ring specific bnp antibodies
WO2006031883A3 (en) Analysis of mhc-peptide binding interactions
WO2006116631A3 (en) Cancer specific pcna isoform binding antibodies and uses thereof
WO2007009018A3 (en) Il-6 binding proteins
ATE405837T1 (en) SOLID PHASE IMMUNOCHROMATOGRAPHIC TESTING METHODS
DE602007007624D1 (en) Proteome-wide quantification of small molecules bound to target cellular proteins
WO2005059517A3 (en) Toll-like receptor assays
WO2008021614A3 (en) Coded particle arrays for high throughput analyte analysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2571431

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11645273

Country of ref document: US

Ref document number: 11645188

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007518318

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005258281

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005789058

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005258281

Country of ref document: AU

Date of ref document: 20050624

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005258281

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005789058

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11645273

Country of ref document: US

Ref document number: 11645188

Country of ref document: US